User:JonStark22/Cannabigerolic acid

Cannabigerolic acid (CBGA) is the acidic form of cannabigerol (CBG). It is a dihydroxybenzoic acid and olivetolic acid in which the hydrogen at position 3 is substituted by a geranyl group. It is a biosynthetic precursor to Delta-9-tetrahydrocannabinol, which is the principal psychoactive constituent of the Cannabis plant. It is also a diterpenoid, a polyketide, a member of resorcinols and a phytocannabinoid. It derives from an olivetolic acid. It is a conjugate acid of a cannabigerolate.

Treatment for Epilepsy
Cannabigerolic acid (CBGA) along with Cannabidiol (CBD) have a long history of being safe for oral consumption for illnesses such as Dravet syndrome and Lennox-Gastaut (LGS) syndrome that cause epilepsy in children. Treatment with CBD products are used for children (unregulated), they contain very low amounts of CBD but are fortified with various other phytocannabinoids for their anti-convulsion effects. A recent study was done to observe the effects CBD and other phytocannabinoids would have on mice as preventative and treatment measures for seizures and epilepsy. Researchers concluded that CBGA (1400 mg) had the most significant anticonvulsant effects on both spontaneous and hypothermic-induced seizures on the mice. But researchers also concluded that in the 6hz test model of therapy-resistant limbic seizures and in high doses (2500 mg +) CBGA also displayed proconvulsant effects and increased frequency of spontaneous seizures. CBGA medical uses are relatively still unknown but hold much promise for treatment of uncontrollable epilepsy in children, in another study scientists recognized one of the main issues of CBGA was its weak brain penetrability and its instability as a molecule. Researchers discovered that through esterification of CBGA, CBGA methyl-ester was found to be much more stable form and increases brain penetration from 2% with normal CBGA compared to 13% with CBGA methyl-ester. Increasing brain penetrability and chemical stability brings clinical use of CBGA and other phytocannabinoids one step closer to becoming the next-generation anti-seizure and anticonvulsive medications. Furthermore, research has also shown that CBGA has also shown the ability to reduce interictal epileptiform discharges (IEDs). Interictal epileptiform discharges is a less known topic and therefore less researched but are more frequent in patients fighting epilepsy than seizures are. IED's are "large intermittent electrophysiological events observed between seizures in patients with epilepsy". CBGA has been proven to help individuals reduce the amount and duration of IED's as well as improved seizure control for both children and adults suffering from epilepsy. Also, important to note that researches have shown that Cannabidiol (CBD) along with other phytocannabinoids such as CBGA shows ability to improve mood and alleviate depression among patients suffering from epilepsy. As it stands today, CBD along with CBGA and other phytocannabinoids anticonvulsive and anti-seizure properties is not known, all though it is theorized that it effects vanilloid, serotonin and, G-protein coupled receptors along with its anti-inflammatory properties. Regarding the previous research mentioned on CBGA effects on mice with induced epilepsy, CBGA was found to interact with TRPV1 channels, GABAA and GPR55 receptors which have all been linked to as epilepsy-relevant targets.